Evaluation and Management of Delayed Puberty and Short Stature in Adolescent Males

Initial Assessment and Laboratory Workup

The initial clinical assessment should include measurement of serum prolactin, bone age radiograph, complete blood count, comprehensive metabolic panel, thyroid function tests, and assessment of FSH, LH, and testosterone to differentiate constitutional delay from pathologic causes requiring intervention, as recommended by the Endocrine Society 1, 2, 3, 4
Documenting birth parameters, such as weight, length, and head circumference, can help identify intrauterine growth restriction, which suggests different etiologies than postnatal-onset short stature, according to the American Academy of Pediatrics 3, 5
Obtaining parental heights to calculate midparental height and assess genetic potential for growth is essential, as stated by the American Academy of Pediatrics 3, 4, 5
Assessing growth velocity over the past 6-12 months can help distinguish between constitutional delay and pathologic short stature, as recommended by the Genetics in Medicine journal 6, 4
Evaluating body proportions, such as the sitting height to standing height ratio, can help distinguish proportionate from disproportionate short stature, according to the American Academy of Pediatrics 3, 5
Documenting dysmorphic features, including facial characteristics, limb abnormalities, and any major or minor malformations, can suggest chromosomal abnormalities or genetic syndromes, as stated by the Genetics in Medicine journal 6, 3, 5

Serum prolactin measurement is crucial to exclude prolactinoma, which commonly presents with delayed puberty and growth failure, as recommended by the Endocrine Society 1, 2, 7
FSH, LH, and testosterone levels can help differentiate hypogonadotropic hypogonadism from hypergonadotropic hypogonadism, according to the Endocrine Society 1, 2, 4
Thyroid function tests, such as TSH and free T4, can help exclude hypothyroidism as a reversible cause of delayed puberty, as stated by the American Thyroid Association 3, 4
Bone age radiograph can determine growth potential and differentiate constitutional delay from familial short stature, according to the American Academy of Pediatrics 3, 4, 5

Constitutional delay of growth and puberty is characterized by normal growth velocity, delayed bone age, and family history of late puberty, as stated by the American Academy of Pediatrics 3, 4, 5
Pathologic hypogonadotropic hypogonadism is characterized by low FSH, LH, and testosterone levels, and may require long-term testosterone replacement therapy, according to the Endocrine Society 4
Pathologic hypergonadotropic hypogonadism is characterized by elevated FSH and LH levels, and may require lifelong testosterone replacement therapy, as stated by the Endocrine Society 4
Genetic and syndromic causes, such as Turner syndrome and SHOX gene mutations, should be considered in patients with dysmorphic features or disproportionate short stature, according to the Genetics in Medicine journal 6, 3, 4

Missing Turner syndrome or its variants by failing to obtain karyotype in boys with unexplained short stature and dysmorphic features, as stated by the American Academy of Pediatrics 3, 4
Overlooking prolactinoma by not measuring prolactin in all cases of delayed puberty with growth failure, according to the Endocrine Society 1, 2, 7
Initiating testosterone therapy without bone age assessment, which risks premature epiphyseal closure and compromised final adult height, as stated by the Endocrine Society 4
Assuming constitutional delay at age 14 without excluding pathologic causes, as recommended by the American Academy of Pediatrics 3, 4, 5
Failing to monitor bone age every 6 months during androgen treatment, which can compromise final height, according to the Endocrine Society 4